Design and baseline characteristics of the LANDMARK study

[1]  Y. Wada,et al.  Evaluation of Aortic Calcification With Lanthanum Carbonate vs. Calcium‐Based Phosphate Binders in Maintenance Hemodialysis Patients With Type 2 Diabetes Mellitus: An Open‐Label Randomized Controlled Trial , 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[2]  S. Fukuhara,et al.  Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  M. Dorgan,et al.  Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis , 2013, The Lancet.

[4]  Takayuki Hamano,et al.  An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2010) , 2012, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  N. Hirawa,et al.  Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  K. Polkinghorne,et al.  Attenuation of aortic calcification with lanthanum carbonate versus calcium‐based phosphate binders in haemodialysis: A pilot randomized controlled trial , 2011, Nephrology.

[7]  T. Shigematsu,et al.  Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients , 2010, Clinical and Experimental Nephrology.

[8]  Jiannong Liu,et al.  Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[9]  R. Pratt,et al.  Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy , 2009, Current medical research and opinion.

[10]  T. Shigematsu,et al.  Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia. , 2008, Clinical nephrology.

[11]  R. Santos,et al.  Phosphate Binder Impact on Bone Remodeling and Coronary Calcification – Results from the BRiC Study , 2008, Nephron Clinical Practice.

[12]  P. Kessler,et al.  A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  K. Nitta,et al.  Effects of Sevelamer on the Progression of Vascular Calcification in Patients on Chronic Haemodialysis , 2008, Nephron Clinical Practice.

[14]  T. Akizawa,et al.  CKD-MBD: impact on management of kidney disease , 2007, Clinical and Experimental Nephrology.

[15]  L. Kazis,et al.  Survival in end stage renal disease: calcium carbonate vs. sevelamer , 2007, Journal of clinical pharmacy and therapeutics.

[16]  L. Russo,et al.  The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. , 2007, Kidney international.

[17]  P. Raggi,et al.  Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. , 2007, Kidney international.

[18]  P. Raggi,et al.  Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  P. Raggi,et al.  Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. , 2005, Kidney international.

[20]  B. Kestenbaum,et al.  Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  E. Ritz,et al.  Hyperphosphatemia in Renal Failure , 2004, Blood Purification.

[22]  G. Chertow,et al.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.

[23]  P. Raggi,et al.  Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification. , 2004, Clinical nephrology.

[24]  P. Raggi,et al.  Determinants of progressive vascular calcification in haemodialysis patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  G. London,et al.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  A. Fournier,et al.  Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  P. Raggi,et al.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.

[28]  J. Blacher,et al.  Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal Disease , 2001, Hypertension.

[29]  M. McKee,et al.  Phosphate regulation of vascular smooth muscle cell calcification. , 2000, Circulation research.

[30]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[31]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  R. Frye,et al.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. , 1975, Circulation.

[33]  WGAusten,et al.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association , 1975 .

[34]  E. Roth,et al.  Physical Activity and Exercise Recommendations for Stroke Survivors A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. , 2014 .

[35]  S. Nakai,et al.  An overview of regular dialysis treatment in Japan (As of December 31, 2012) , 2014 .

[36]  W. Suki.  Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. , 2008, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[37]  P. Raggi,et al.  Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. , 2004, The Journal of heart valve disease.

[38]  C. Zoccali,et al.  Novel cardiovascular risk factors in end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[39]  B. Boudailliez,et al.  Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. , 1992, Nephron.